Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Short Interest Update

Inventiva S.A. Sponsored ADR (NASDAQ:IVA) was the target of a large increase in short interest in January. As of January 30th, there was short interest totaling 630,577 shares, an increase of 300.2% from the January 15th total of 157,548 shares. Currently, 0.6% of the company’s stock are short sold. Based on an average trading volume of 658,211 shares, the days-to-cover ratio is currently 1.0 days. Based on an average trading volume of 658,211 shares, the days-to-cover ratio is currently 1.0 days. Currently, 0.6% of the company’s stock are short sold.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on IVA shares. Wall Street Zen raised Inventiva to a “hold” rating in a research report on Saturday, October 18th. Leerink Partners assumed coverage on Inventiva in a report on Monday, January 12th. They issued an “outperform” rating and a $12.00 price objective for the company. Barclays assumed coverage on Inventiva in a research report on Tuesday, January 27th. They set an “overweight” rating and a $18.00 price objective for the company. Guggenheim reduced their target price on shares of Inventiva from $13.00 to $11.00 and set a “buy” rating on the stock in a research report on Tuesday, November 18th. Finally, Wolfe Research raised shares of Inventiva to a “strong-buy” rating in a research report on Thursday, November 6th. Two research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Buy” and an average price target of $16.22.

Inventiva Price Performance

Shares of NASDAQ:IVA traded down $0.15 on Wednesday, hitting $6.14. 387,845 shares of the company traded hands, compared to its average volume of 593,584. The stock has a 50 day simple moving average of $5.28 and a 200-day simple moving average of $4.96. Inventiva has a 52 week low of $2.30 and a 52 week high of $7.98.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Creative Planning purchased a new stake in shares of Inventiva during the second quarter valued at approximately $32,000. Wealth Enhancement Advisory Services LLC lifted its position in Inventiva by 55.6% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 25,770 shares of the company’s stock valued at $142,000 after acquiring an additional 9,212 shares in the last quarter. Millennium Management LLC bought a new position in Inventiva in the 3rd quarter valued at approximately $649,000. NewEdge Advisors LLC purchased a new stake in Inventiva during the 3rd quarter valued at $116,000. Finally, UBS Group AG increased its holdings in shares of Inventiva by 28,881.6% in the 4th quarter. UBS Group AG now owns 2,643,702 shares of the company’s stock worth $12,293,000 after purchasing an additional 2,634,580 shares in the last quarter. Institutional investors own 19.06% of the company’s stock.

About Inventiva

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.